Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of subcutaneous (SC) PL-3994, relative to placebo in subjects with controlled hypertension. Including in this evaluation is the effect PL3994 has on blood pressure.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Palatin Technologies

Criteria

Inclusion Criteria:

• Subjects must have had a diagnosis of essential hypertension for at least 1 year, per subject verbal history

• Subject must be on a stable dose of at least one, but not more than 3 antihypertensive medications for at least 3 months, per subject verbal history.

• Subject must have a systolic blood pressure at screening between 100 and 150 mmHg, and diastolic blood pressure must not exceed 105 mmHg.

Exclusion Criteria:

• Subject weight greater than 100 kg or less than 50 kg.

• Any significant medical condition or abnormal safety laboratory results which, in the judgement of the Investigator would place the subject at significant risk.